Fig. 3
The loss of Lyve-1 protects against hepatic melanoma metastasis. A After spleen injection of MC38 colorectal carcinoma cells the numbers of macroscopic visible hepatic metastases (50 vs. 39.2, P = 0.5563) were quantified in Ctrl (n = 5) and Lyve-1−/− (n = 5) mice at day 21. Photographs of livers with CRC metastases are shown. Scale bars: 1 cm. B Following intrasplenic injection of B16F10 luc2 melanoma cells, macroscopic visible hepatic metastases were quantified in Ctrl (n = 12) and Lyve-1−/− (n = 14) mice at day 14 (38.25 vs. 11.36, P = 0.0093, Mann–Whitney U-test). Representative photographs of livers with metastases are shown. Scale bars: 1 cm. C Ex vivo BLI images of Ctrl (n = 12) and Lyve-1−/− (n = 14) livers. Quantification of livers determined as region of interest at day14 after intrasplenic injection of B16F10 luc2 melanoma cells (P = 0.0356, Mann–Whitney U-test). Color scale: min = 1.67 × 106 p/sec/cm2 /sr; max = 2.46 × 107 p/sec/cm2 /sr. D WT31 cells were injected into the tail vein and melanoma liver metastases (19.15 vs. 8.0, P = 0.0408, Mann–Whitney U-test) were counted in Ctrl (n = 13) and Lyve-1−/− (n = 14) mice at day 19. Photographs of livers are displayed. Scale bars: 1 cm. E Ex vivo BLI images of Ctrl (n = 5) and Lyve-1−/− (n = 4) livers. Quantification of livers determined as region of interest (P = 0.7508) 90 min after intrasplenic injection of B16F10 luc2 melanoma cells. Color scale: min = 5.0 × 104 p/sec/cm2 /sr; max = 6.6 × 104 p/sec/cm2 /sr. Data information: * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns not significant